CBD reduced a "don't eat me" signal on leukemia cells and triggered cell death through a specific mitochondrial pathway | Research

The takeaway

CBD downregulated CD47 expression (a signal that helps cancer cells evade immune destruction) and induced apoptosis in leukemic cells through a mechanism involving VDAC-1 oligomerization at the mitochondria.

Cancer biology researchers, hematology-oncology researchers, cannabinoid pharmacologists

CBD reduced CD47 "don't eat me" signal on leukemia cells via VDAC-1 pathway

What the researchers found

CBD reduced CD47 surface expression and triggered apoptosis in Jurkat leukemic cells. These effects were not blocked by cannabinoid receptor 2 agonists, antagonists, or anion channel blockers, but were significantly rescued by a VDAC-1 oligomerization inhibitor, revealing a specific mitochondrial pathway. Similar but weaker effects were observed in primary human T cells.

Why it matters

CD47 is a "don't eat me" signal that cancer cells use to avoid immune destruction. Understanding how CBD reduces this signal could inform new combination therapy approaches for aggressive blood cancers.

The numbers in context

CBD downregulated CD47 expression dose-dependently; effects significantly rescued by VDAC-1 oligomerization inhibitor; similar effects in primary human CD4+ T cells at reduced levels; not rescued by CBR-2 agonist, CBR-2 antagonist, or anion channel blocker

How the study worked

In vitro studies using Jurkat cells (T-cell acute lymphoblastic leukemia line) and human peripheral blood mononuclear cells under various culture conditions, CBD concentrations, and with or without different receptor agonists, antagonists, and channel blockers.

What this study cannot tell us

In vitro study using cell lines may not reflect in vivo tumor biology. CBD also affected normal T cells, raising safety concerns for immunocompromised patients. Concentrations used may not be achievable in humans. No animal or clinical data.

How to read the evidence

Preliminary: in vitro study with cell lines. While the mechanistic findings are detailed, no animal or human data supports clinical applicability.

When this study was published

2026 publication using Jurkat leukemic cell line and primary human cells.

The bigger picture

This adds mechanistic detail to the growing literature on CBD and cancer. By identifying the VDAC-1 oligomerization pathway, it moves beyond the general observation that CBD kills cancer cells to explaining how it might work.

Questions still open

Would CBD-induced CD47 reduction make leukemia cells more susceptible to immune attack in vivo? Could the effect on normal T cells limit CBD use in cancer patients? What CBD concentrations would be needed therapeutically?

Common questions

What is CD47 and why does it matter for cancer?

CD47 is a surface protein that sends a "don't eat me" signal to immune cells. Cancer cells often overexpress CD47 to avoid being destroyed by the immune system. CBD reduced this signal on leukemia cells.

How does CBD kill leukemia cells according to this study?

Through VDAC-1 oligomerization at the mitochondria, which triggers programmed cell death (apoptosis). This pathway was independent of cannabinoid receptor 2, suggesting CBD uses a non-classical mechanism.

Read the original research

Cannabidiol Regulates CD47 Expression and Apoptosis in Jurkat Leukemic Cells Dependent upon VDAC-1 Oligomerization.

Pharmaceuticals (Basel, Switzerland), 19(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Lixing; Samarani, Suzanne; Fadzeyeva, Evgenia; Vigano, MariaLuisa; As'sadiq, Alia; Vulesevic, Branka; Ahmad, Ali; Costiniuk, Cecilia T. (2026). Cannabidiol Regulates CD47 Expression and Apoptosis in Jurkat Leukemic Cells Dependent upon VDAC-1 Oligomerization.. Pharmaceuticals (Basel, Switzerland), 19(1). https://doi.org/10.3390/ph19010095